Patients with Asian-type DEL can safely be transfused using RhD-positive blood
Blood · 2023
DOI: 10.1182/blood.2022018152 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Blood, 2023. Verfasst von Yanli Ji und 28 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, China. Hauptthemen laut MEDLINE: Rh-Hr Blood-Group System, Blood Group Antigens. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
Red blood cells (RBCs) of the Asian-type DEL phenotype express few RhD proteins and are typed as serologic RhD-negative (D-) in routine testing. RhD-positive (D+) RBC transfusion for Asian-type DEL patients has been proposed but has not been generally adopted due to a lack of direct evidence regarding its safety and underlying mechanism. We performed a single-arm multicenter clinical trial to document the outcome of D+ RBC transfusion in Asian-type DEL patients; none of the recipients (0/42; 95% confidence interval, 0%-8.40%) developed alloanti-D after a median follow-up of 226 days. We conducted a large retrospective study to detect alloanti-D immunization in 4,045 serologic D- pregnant women throughout China; alloanti-D was found only in true D- individuals (2.63%, 79/3,009), but not in those with Asian-type DEL (0/1,032). We further retrospectively examined 127 serologic D- pregnant women who had developed alloanti-D and found none with Asian-type DEL (0/127). Finally, we analyzed RHD transcripts from Asian-type DEL erythroblasts and examined antigen epitopes expressed by various RHD transcripts in vitro, finding a low abundance of full-length RHD transcripts (0.18% of the total) expressing RhD antigens carrying the entire repertoire of epitopes, which could explain the immune tolerance against D+ RBCs. Our results provide multiple lines of evidence that individuals with Asian-type DEL cannot produce alloanti-D when exposed to D+ RBCs following transfusion or pregnancy. Therefore, we recommend considering D+ RBC transfusion and discontinuing anti-D prophylaxis in Asian-type DEL patients, including pregnant women. This clinical trial is registered at www.clinicaltrials.gov as NCT03727230.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, China.
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
- MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou, China.
- RNA Biomedical Institute, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- State Key Laboratory of Organ Failure Research, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
- Department of Blood Transfusion, Guangdong Provincial People's Hospital, (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
ORCID-Profile: Yanli Ji, Yalin Luo, Jizhi Wen, Shuangshuang Jia, Chunquan Ou, Sentot Santoso, Yann Fichou, Willy Albert Flegel, Chengyao Li, Rui Zhang, Yongshui Fu
Förderung
- Intramural NIH HHS
Zitieren
APA
Ji, Y., Luo, Y., Wen, J., Sun, Y., Jia, S., Ou, C., Yang, W., Chen, J., Ye, H., Liu, X., Liang, Y., Lu, Z., Feng, Y., Wu, X., Xiao, M., Mo, J., Zhou, Z., Wang, Z., Liao, Z., …, & Fu, Y. (2023). Patients with Asian-type DEL can safely be transfused using RhD-positive blood. Blood. https://doi.org/10.1182/blood.2022018152
Vancouver
Ji Y, Luo Y, Wen J, Sun Y, Jia S, Ou C, et al. Patients with Asian-type DEL can safely be transfused using RhD-positive blood. Blood. 2023. doi:10.1182/blood.2022018152
BibTeX
@article{Ji2023,
author = {Ji, Yanli and Luo, Yalin and Wen, Jizhi and Sun, Yuanfan and Jia, Shuangshuang and Ou, Chunquan and Yang, Wenbing and Chen, Jingwang and Ye, Hanshen and Liu, Xiangfu and Liang, Yongneng and Lu, Zhigang and Feng, Ying and Wu, Xinzhong and Xiao, Muzhou and Mo, Jiankun and Zhou, Zhenhai and Wang, Zhen and Liao, Zhijian and Chen, Junhu and Wei, Ling and Luo, Guangping and Santoso, Sentot and Fichou, Yann and Flegel, Willy Albert and Shao, Chaopeng and Li, Chengyao and Zhang, Rui and Fu, Yongshui},
title = {Patients with Asian-type DEL can safely be transfused using RhD-positive blood},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022018152}
}
EUVIMED